alt text alt text

 

DurAVR™

Transcatheter Heart Valve 

BETTER SCIENCE. BETTER DESIGN.

Anteris’ DurAVR™ THV 3D single-piece, native-shaped valve delivers superior performance with the promise of durability – its innovative design is engineered to last the remainder of a patient’s lifetime. The proven benefits of its patented ADAPT® tissue technology, paired with the unique single-piece, native valve shape, valuably positions DurAVR™ valve to deliver a game-changing treatment for patients worldwide with aortic stenosis - providing a needed solution to the challenges physicians are facing today with their patients.

alt text alt text

DurAVR™ THV

ADVANCING TISSUE SCIENCE FOR PERFORMANCE AND DURABILITY

 

DurAVRTM 3D single-piece, shaped valve is designed like the native aortic valve

  • Larger EOA
  • More consistent laminar flow
  • Improved exercise capacity

 

 ADAPT® Anti-calcification Process1

  • Proprietary tissue processing designed to neutralize bovine pericardium tissue to resist calcification
  • Clinical durability with no calcification in over 10 years

 

 

 

 

ComASUR™ Delivery System

 

 

 

 

BUILT FOR PREDICTABILITY



  • Predictable, familiar, steerable balloon expandable delivery and deployment
  • Rotational control for commissural alignment and optimized coronary access
ComASUR

 

REFERENCES

[1] Neethling W, Rea A, Forster G and Bhirangi K (2020) Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes. Front. Pediatr. 8:198. doi: 10.3389/fped.2020.00198Neethling W, Rea A, Forster G and Bhirangi K (2020) Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes. Front. Pediatr. 8:198. doi: 10.3389/fped.2020.00198

 

LATEST ANTERIS NEWS

Tile1 TILE1 MOBILE

Anteris CEO Wayne Paterson interview on Proactive Investor

The valve world is talking about natural-like aortic valve shape and function of DurAVR THV

Watch Replay
tile2 Desktop image tile1 mobile

TCT 2022 Innovation in TAVR Presentation

First-in-human Study Results With the Novel Anteris DurAVR™ 3D Single-Piece TAVR Device

Presented by:
Vinnie Bapat, MD
Abbott Northwestern, MN
ASX Announcement
tile3desktop mobtile3

TCT 2022 Preliminary Results Presented

Impact of Novel Leaflet Design on Hemodynamics &
Transvalvular Physiology

Comparison of DurAVR™ THV, TAVR, SAVR, &
Native Aortic Valve Using Cardiac MRI

ASX Announcement
tile4 desktop mobtile4

Anteris Investor Webcast at TCT 2022

Anteris Leadership and Physician Thought Leaders to

Share Results of the DurAVR™ THV First-in-human

30-day Results

TCT 2022 CONFERENCE
Virtual Presentation
Watch Replay